UNITEDHEALTH GROUP INC 8-K

What Happened
UnitedHealth Group (UNH) filed an 8‑K reporting the results of its 2026 Annual Meeting of Shareholders held June 1, 2026. A total of 768,066,717 shares were represented. All nine director nominees were re-elected for one-year terms. The non‑binding advisory vote on executive compensation was approved, Deloitte & Touche LLP was ratified as the company’s independent auditor for 2026, and a shareholder proposal to require any board chair to be independent was not approved.

Key Details

• 768,066,717 shares represented at the Annual Meeting.
• Directors: all nine nominees elected. Vote percentages For ranged from 89.68% (Charles Baker) to 98.96% (Kristen Gil); other notable For votes included John Noseworthy, M.D. 98.11% and F. William McNabb III 97.13%.
• Executive compensation (non‑binding) approved: 559,434,838 For; 117,731,618 Against; 1,163,998 Abstain — 82.74% For (abstentions counted as Against for this vote).
• Auditor ratification: Deloitte & Touche LLP ratified with 729,713,547 For (95.00%). Shareholder proposal to require an independent board chair failed: 137,347,215 For (20.24%); 537,634,392 Against.

Why It Matters
The results signal shareholder support for the current board and leadership continuity at UnitedHealth Group, and investor approval (non‑binding) of the company’s executive pay approach. Ratification of Deloitte & Touche maintains the company’s auditor relationship for 2026. The rejection of the independent‑chair proposal means the board’s existing governance structure will remain unchanged.